Intelligent Bio SolutionsNASDAQ: INBS

Unaudited quarterly revenue increased 10% year-on-year and 20% quarter-on-quarter Higher-margin, recurring cartridge revenue expected to surpass reader revenue as primary driver Expanded distribution network in Saudi Arabia NEW YORK, Oct. 29, 2024 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced preliminary unaudited revenue results for the fiscal first quarter ended September 30, 2024. The Company expects unaudited revenue of approximately $0.87 million for the three months ended September 30, 2024, representing an increase of 10% year-on-year and 20% quarter-on-quarter.

New York, New York--(Newsfile Corp. - October 16, 2024) - Intelligent Bio Solutions Inc. (NASDAQ: INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced that its management team will present in the upcoming LD Micro Main Event XVII on October 28-30, 2024, in Los Angeles. LD Micro Main Event XVII Dates: October 28-30, 2024 Location: Luxe Sunset Boulevard Hotel, Los Angeles, CA Presentation Day and Time: October 30 at 10:00 a.m.

NEW YORK, Sept. 27, 2024 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced the successful completion of in-clinic testing proposed to the FDA earlier this year in the Company's clinical study plan.

NEW YORK, Sept. 25, 2024 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced that Thanet Earth, the UK's largest greenhouse complex, has adopted its Intelligent Fingerprinting Drug Screening System for in-house drug testing.

- Fourth-quarter revenue of $0.73 million, up 64% year-over-year – - Full-year revenue of $3.11 million, up 148% year-over-year – - As of June 30, 2024, the Company had $6.30 million in cash - NEW YORK, Sept. 19, 2024 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, announced its financial results for the fiscal fourth quarter and full-year ended June 30, 2024, and provided a business update.

NEW YORK, Sept. 11, 2024 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a leader in non-invasive drug testing technology, today announced that its management team will participate in the Sidoti Small-Cap Virtual Conference being held on September 18-19, 2024.

NEW YORK, Sept. 05, 2024 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced its progress toward completion of the clinical study plan required for its FDA 510(k) submission.

NEW YORK, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (NASDAQ: INBS) (“INBS” or the “Company”), a leader in non-invasive drug testing technology, today announced significant growth in its customer employee base, reporting a 118% fiscal year-over-year increase in the estimated total number of employees across its customer base.

NEW YORK, Aug. 13, 2024 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (NASDAQ: INBS) provides an overview of the increasing prevalence of on-the-job drug use across critical sectors such as construction, manufacturing, transport and warehousing, mining, and automotive. As the need for robust drug testing solutions intensifies, we believe that our company is positioned to lead the way in providing innovative, non-invasive drug testing technologies.